Pharmacotherapy of Antipsychotic-Induced Movement Disorders

This presentation on pharmacotherapy of antipsychotic-induced movement disorders will review incorporating into practice the 2021 American Psychiatric Association recommendations on managing antipsychotic-induced parkinsonism, acute dystonia, akathisia, and TD; the rationale for avoiding routine or prolonged anticholinergic use to manage antipsychotic-related parkinsonism or dystonia; the latest recommendations on effective TD management; and the differences in deutetrabenazine and valbenazine, the VMAT2 inhibitors that are approved by the FDA for TD.
Jonathan M. Meyer, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 2.73 MB
Released: December 8, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
Intra-Cellular Therapies, Inc.
Neurocrine Biosciences, Inc.
Sage Therapeutics
Sunovion
Supernus Pharmaceuticals, Inc.

Related Content

Expert guidance on accurately diagnosing bipolar depression in patients who may not present in a manic or hypomanic episode from Clinical Care Options (CCO)

Greg W. Mattingly, MD Released: July 6, 2022

Slides from a presentation that educates clinicians on the identification and management of tardive dyskinesia.

Christoph U. Correll, MD Robert O. Cotes, MD Released: May 11, 2022

Slides from a presentation that educates clinicians on antipsychotic treatment of schizophrenia.

Christoph U. Correll, MD Robert O. Cotes, MD Released: May 11, 2022

Slides from a presentation that educates clinicians on managing major depression.

Manish Jha, MD Greg W. Mattingly, MD Released: May 11, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings